Noninvasix, Inc. Accepted to Present Novel Fetal Welfare Monitoring System at 2015 Texas Life Science Forum
Houston, TX, May 07, 2015 --(PR.com)-- A first-in-class technology using light and sound to monitor fetal welfare during late-stage labor will be presented by medical device startup Noninvasix, Inc. to an audience of angel investors, venture capital firms and top biotech industry players during the 2015 Texas Life Science Forum. The one-day conference, held in collaboration between Rice Alliance for Technology and Entrepreneurship, BioHouston and the Texas Healthcare & Bioscience Institute, will take place Wednesday, May 20 from 8 a.m. – 6:30 p.m. at 6500 Main Street in Houston.
Selected from hundreds of applications, 48 Texas startups with promising biotech innovations will each give four-and-a-half minute presentations highlighting their technology, team and vision at the Forum, which provides emerging biotech companies with exposure to potential investors, industry partners, mentors, and customers as well as others who support the Texas entrepreneurial ecosystem.
“We’re pleased to be invited back to present our patient monitoring technology at the Forum. This is a great opportunity to provide a progress update to those already familiar with our device and educate potential new partners who haven’t heard of optoacoustics,” said Noninvasix CEO Graham Randall, Ph.D.
In collaboration with obstetricians at University of Texas Medical Branch at Galveston, Noninvasix’s team of engineers and researchers have designed a small fetal probe that uses pulsed laser light to produce an acoustic wave response, which accurately measures the baby’s brain oxygenation levels during late-stage labor. In addition to the reduced incidence of unnecessary cesarean sections, this noninvasive monitoring technology is expected to reduce the risk of severe neonatal morbidity including cerebral palsy.
Company presentations start at 1 p.m. at Rice University’s BioScience Research Collaborative. For more information on the Texas Life Science Forum, visit http://txlifescienceforum.org.
About Noninvasix, Inc.
Using patented optoacoustic technology, Galveston, Texas-based Noninvasix, Inc. has developed a solution for the safe, accurate and non-invasive monitoring of fetal welfare during labor and delivery. Noninvasix’s undertaking to significantly improve outcomes for mother and baby during labor, while reducing malpractice lawsuits and premiums, is backed by 15 years of optoacoustic research and more than $6.5 million in research grants. For more information, visit www.noninvasix.com.
Selected from hundreds of applications, 48 Texas startups with promising biotech innovations will each give four-and-a-half minute presentations highlighting their technology, team and vision at the Forum, which provides emerging biotech companies with exposure to potential investors, industry partners, mentors, and customers as well as others who support the Texas entrepreneurial ecosystem.
“We’re pleased to be invited back to present our patient monitoring technology at the Forum. This is a great opportunity to provide a progress update to those already familiar with our device and educate potential new partners who haven’t heard of optoacoustics,” said Noninvasix CEO Graham Randall, Ph.D.
In collaboration with obstetricians at University of Texas Medical Branch at Galveston, Noninvasix’s team of engineers and researchers have designed a small fetal probe that uses pulsed laser light to produce an acoustic wave response, which accurately measures the baby’s brain oxygenation levels during late-stage labor. In addition to the reduced incidence of unnecessary cesarean sections, this noninvasive monitoring technology is expected to reduce the risk of severe neonatal morbidity including cerebral palsy.
Company presentations start at 1 p.m. at Rice University’s BioScience Research Collaborative. For more information on the Texas Life Science Forum, visit http://txlifescienceforum.org.
About Noninvasix, Inc.
Using patented optoacoustic technology, Galveston, Texas-based Noninvasix, Inc. has developed a solution for the safe, accurate and non-invasive monitoring of fetal welfare during labor and delivery. Noninvasix’s undertaking to significantly improve outcomes for mother and baby during labor, while reducing malpractice lawsuits and premiums, is backed by 15 years of optoacoustic research and more than $6.5 million in research grants. For more information, visit www.noninvasix.com.
Contact
Noninvasix
Anna Drake
713-510-0500
Anna Drake
713-510-0500
Contact
Categories